Skip to content

Real-world study of antithrombotic strategies after gastrointestinal bleeding

Real-world study of antithrombotic strategies after gastrointestinal bleeding

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064063
Enrollment
Unknown
Registered
2022-09-25
Start date
2022-09-25
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

The antithrombotic treatment group was restored within 7 days.:none
The antithrombotic treatment group was not restored within 7 days.:none
endoscopy group:none
No endoscopy group:none
Resuming therapy group:none
No resuming group:none
Uninterrupted group:none

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged >= 18 years, regardless of gender, who received antithrombotic therapy (including antiplatelet or anticoagulant therapy) within 30 days before enrollment and required hospitalization due to gastrointestinal bleeding events; 2. There is obvious bleeding in the gastrointestinal tract and bleeding in the gastroduodenum and small intestine confirmed by gastroscope or enteroscopy; 3. Non-overt gastrointestinal bleeding accompanied by a decrease in hemoglobin of more than 2 g/L; 4. Accompanied by typical gastroduodenal ulcer symptoms for more than 3 days and confirmed by gastroscopy to have multiple erosive lesions accompanied by peptic ulcer symptoms for more than 3 days, or evidence of gastric perforation and obstruction.

Exclusion criteria

Exclusion criteria: 1. In addition to digestive bleeding caused by peptic ulcers, such as varicose vein bleeding caused by portal hypertension, small intestinal malformations, Crohn's disease, ulcerative colitis, Meckel's diverticulum, etc.; 2. Blood system diseases (abnormal blood clotting function); 3. Gastrointestinal tumors; 4. Pregnancy; 5. Refusal to sign informed consent or withdraw from the study.

Design outcomes

Primary

MeasureTime frame
Rebleeding events within 90 days;Rebleeding events;Major Cardiovascular and Cerebrovascular Adverse Events within 90 days;Major Cardiovascular and Cerebrovascular Adverse Events;Antithrombotic strategy;Acid suppression strategy;

Countries

China

Contacts

Public ContactHuang Rongchong

Beijing Friendship Hospital, Capital Medical University

rchuang@aliyun.com+86 18841182000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026